ArticleJournal of biological engineering2026
An advanced genome engineering platform for Komagataella phaffii enabling versatile in vivo DNA assembly and multiplex integration.
Article in Journal of biological engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring the immunological effects of antibody-drug conjugates.Nature reviews. Clinical oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe transition toward a sustainable bioeconomy necessitates the development of robust microbial platforms capable of C1 chemical valorization, particularly the conversion of methanol into high-value chemicals. Komagataella phaffii is a premier methylotrophic host for such applications due to its natural methanol utilization pathways and high-density fermentation capabilities. However, its potential as a C1-based synthetic biology chassis has been hampered by inefficient homologous recombination and the technical complexity of multigene pathway integration. To accelerate the design-build-test-learn (DBTL) cycle for methanol-based biomanufacturing, a more sophisticated and high-throughput genome engineering toolkit is required.
resultsWe report the development of an HR-enhanced K. phaffii chassis (dKR) achieved by synergistically deleting Ku70 and overexpressing RAD52 at the chromosomal level. This engineering markedly improved the robustness and reproducibility of CRISPR/Cas9-mediated genome editing, increasing integration efficiency from 15.3% in the wild-type to 68.1% in the dKR chassis when using short 50-bp homology arms. The platform demonstrated exceptional capacity for vector-free multi-fragment assembly, achieving an integration efficiency of 86.5% for nine linear DNA fragments. Furthermore, the implementation of a tRNA-ribozyme CRISPR system enabled simultaneous multi-locus integration at three distinct genomic sites with 44.6% efficiency. Notably, the chassis supported direct in vivo plasmid assembly of ten fragments (9 fragments + 1 backbone) with 44.8% efficiency, effectively bypassing E. coli-based cloning. Functional validation via a carotenoid biosynthetic pathway resulted in β-carotene production while maintaining normal cellular growth and metabolic productivity.
conclusionThis study established a versatile genome-engineering platform that advances K. phaffii from a protein-expression host to a broadly applicable biological engineering chassis. By enabling streamlined cellular design and reproducible multigene integration, the platform supports applications spanning synthetic biology, metabolic engineering, and bioproduction. More broadly, the approach illustrates how rational manipulation of DNA repair pathways can enhance genome engineering performance in non-conventional hosts, providing transferable design principles relevant to biological engineering across multiple domains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.